Earlier this week, Dr Balaji Ganeshan was invited to give a guest lecture at the University Centre Hospitals of Coimbra in Portugal. Dr Ganeshan gave a talk titled: “Quantifying Tumour Heterogeneity with TexRAD Texture Analysis on CT and MRI – Ready for Prime Time?” at the institute for biomedical imaging and life sciences. Furthermore, Dr Ganeshan was given a tour around the modern imaging and nuclear medicine facilities by the head of Radiology, Professor Caseiro Alves and colleagues. Professor Alves will be presenting at the European Gastro abdominal radiology 2018 meeting in Ireland later this year. As part of his keynote lecture he will discuss his research findings using the TexRAD software. Dr Ganeshan said about the visit “I am very impressed by the state-of-the-art facilities available and I look forward to seeing more great research using TexRAD come from this excellent university”.
Researchers at the Princess Alexandra Hospital (Australia) recently published a study demonstrating the potential for the clinical implementation of CT texture analysis (CTTA) in the assessment of tumour heterogeneity in lung cancer. The publication highlighted possible applications of CTTA including; distinguishing between benign and malignant lesions, providing correlates for biological features of the lesions such as gene mutations, indications of tumour aggression and response to treatment. The 18-month prospective observational study provided the TexRAD research software to five radiology and nuclear medicine specialists as a tool to quantify texture parameters in lung tumours. The Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework was applied to identify potential barriers to the clinical implementation of this method into clinical workﬂows. Furthermore, the subsequent delivery of heterogeneity information to the multidisciplinary team (MDT) meeting at which clinical decisions were made was also observed. Survival data was available for 150 of the patients and these outcomes were correlated to reported texture values. In particular, Kurtosis values above the threshold of 0 (n = 78) demonstrated signiﬁcantly poorer survival (P = 0.004). Of a total of 152 lung cancer patients analysed for heterogeneity, 124 (82%) were discussed at the MDT meeting. The TexRAD results were used for research purposes only and were not used to alter any individual patient’s treatment. The study suggests that there is a huge potential for the implementation of quantitative imaging in the assessment of tumour heterogeneity and engagement from radiologists is key to its success.
Please follow the link below for more information
Dr Balaji Ganeshan will be attending the 17th Asian Oceanian Congress of Radiology (AOCR) & 71st National Conference of the Indian Radiological and Imaging Association (IRIA) in Mumbai, India from the 25th-28th January.
We invite those of you in attendance to get in contact with Dr Ganeshan on firstname.lastname@example.org to arrange to meet with him, where he will be happy to discuss TexRAD texture analysis in medical imaging.
Follow the link for more details on the events: https://aocr2018.org/
Dr Balaji Ganeshan presented and gave a demonstration of TexRAD as part of the topic ‘Advances in Medical Imaging’ at the college’s department of radiology on the 3rd of January 2018.
The talk was titled “Quantifying Tumour Heterogeneity with TexRAD Texture Analysis on CT and MRI – Ready for Prime Time?”
Tumour heterogeneity is a well-recognised feature of malignancy associated with increased tumour aggression and treatment resistance. It can be evaluated at genetic, epigenetic and phenotypical levels. Heterogeneity can alter biological and physical factors such as vascularity (angiogenesis), necrosis, fibrosis, proliferation and hypoxia etc. Texture analysis of diagnostic images such as CT, MRI and PET can quantify and provide an objective measurement of heterogeneity which can assist in radiological and oncological practice. TexRAD is a well established and widely published technique of Texture analysis.
The talk’s key discussion points included:
· What does TexRAD texture analysis actually mean?
· Biological correlates
· Clinical validation – prognosis, disease-severity, treatment-response/prediction
· Technical validation
· Clinical utility and cost-effectiveness
TexRAD Ltd is looking forward to attending the Big-Data, Radiomics and A.I. Symposium on the 15th to 16th December 2017 in the City of Reggio Emilia, Italy.
Dr. Balaji Ganeshan will be presenting on TexRAD texture analysis of medical images (CT, MRI) in oncology research and discuss the qualification-process of TexRAD as an imaging biomarker and its potential to translate TexRAD research software into clinical practice.
His presentation will take place on Friday the 15th of December at the Company Symposium 1,
“Research, Products & Work in Progress”. The session commences at 14:05.
The title of the talk will be:
Quantifying Tumour Heterogeneity with TexRAD Texture Analysis on CT and MR Data – Ready for Prime Time?
Follow the link for more details on the symposium: http://www.symposium.it/eventi/2017/big-data-radiomics-artificial-intelligence
TexRAD is pleased be one of the sponsors of this symposium